APPRISS LLC – Trademark Portfolio
Entity Type: 16
APPRISS LLC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 11 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include NARXCARE, RXSENTRY, PMP GATEWAY, SAFESCRIPTS+, and BAMBOO HEALTH. The owner is based in LOUISVILLE, KY.
9901 LINN STATION RD.
SUITE 500
LOUISVILLE, KY 40223
Showing of trademarks Trademarks
Trademark Classifications
APPRISS LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does APPRISS LLC have?
APPRISS LLC has 11 U.S. trademarks filed with the USPTO. Of these, 9 registered, 2 cancelled.
What trademark classes does APPRISS LLC file in?
APPRISS LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 35 (Advertising & Business), Class 45 (Legal & Security Services), Class 38 (Telecommunications). Class 42 covers scientific and technological services; industrial analysis and research services.
What are APPRISS LLC's most well-known trademarks?
APPRISS LLC's registered trademark portfolio includes well-known marks such as NARXCARE, RXSENTRY, PMP GATEWAY, SAFESCRIPTS+, and BAMBOO HEALTH. These are among 9 currently registered trademarks in the portfolio.
What is APPRISS LLC's trademark registration success rate?
APPRISS LLC has a 82% trademark registration rate, with 9 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.